Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 4.2.2019 | EN | Official Journal of the European Union | C 44/46 |

---

Judgment of the General Court of 22 November 2018 — Endoceutics v EUIPO — Merck (FEMIVIA)

(Case T-59/18) [(1)](#ntr1-C_2019044EN.01004601-E0001)

((EU trade mark - Opposition proceedings - Application for EU word mark FEMIVIA - Earlier EU word mark FEMIBION INTIMA - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EU) 2017/1001))

(2019/C 44/58)

Language of the case: English

Parties

Applicant: Endoceutics, Inc. (Quebec, Canada) (represented by: M. Wahlin, lawyer)

Defendant: European Union Intellectual Property Office (represented by: A. Lukošiūtė, acting as Agent)

Other party to the proceedings before the Board of Appeal of EUIPO: Merck KGaA (Darmstadt, Germany)

Re:

Action brought against the decision of the Second Board of Appeal of EUIPO of 27 November 2017 (Case R 280/2017-2), relating to opposition proceedings between Merck and Endoceutics.

Operative part of the judgment

The Court:

|  |  |
| --- | --- |
| 1. | Dismisses the action; |

|  |  |
| --- | --- |
| 2. | Orders Endoceutics, Inc. to pay the costs. |

---

---

[Top](#document1)